{"chunk_id": "medquad__chunk_34450", "source": "medquad", "text": "rength, and reduce glycogen accumulation. A drug called alglucosidase alfa (Myozyme), has received FDA approval for the treatment of infants and children with Pompe disease. Another algluosidase alfa drug, Lumizyme, has been approved for late-onset (non-infantile) Pompe disease.\",NINDS,Pompe Disease\nWhat is the outlook for Pompe Disease ?,\"Without enzyme replacement therapy, the hearts of babies with infantile onset Pompe disease progressively thicken and enlarge. These babies die before the age"}